摘要
目的 对缬草Valeriana officinalis水提取物中的化学成分进行研究。方法 运用正相硅胶柱色谱、ODS反相柱色谱、制备高效液相色谱等分离手段进行分离纯化,采用核磁共振、质谱等多种波谱学技术鉴定化合物的化学结构,并采用Griess法评价其对脂多糖诱导的小胶质细胞BV-2神经炎症的抑制活性。结果 从缬草水提取物中分离得到了12个化合物,分别为tinnevellin-8-O-β-D-glucopyranoside(1)、大黄素-8-O-β-D-吡喃葡萄糖苷(2)、(2R,3S)-肥牛木素(3)、左旋橄榄素-9’-O-β-D-吡喃葡萄糖苷(4)、左旋马尾松树脂醇-3a-O-β-D-吡喃葡萄糖苷(5)、金色酰胺醇乙酸酯(6)、松脂素(7)、8-羟基松脂素(8)、松脂素-4-O-β-D-吡喃葡萄糖苷(9)、8,8’-二羟基松脂素-4-O-β-D-吡喃葡萄糖苷(10)、(2S)-橙皮苷(11)和香蜂草苷(12)。结论 化合物1~4和6均为首次从缬草属植物中分离得到。其中,化合物3~4、6、9、11~12在不影响BV-2的细胞活力前提下,可以抑制脂多糖诱导的BV-2细胞神经炎性因子一氧化氮(NO)的产生。
Objective To study the chemical constituents of the water-soluble extract of Valeriana officinalis.Methods Silica gel and ODS column chromatography,preparative high-performance liquid chromatography were applied for isolation of constituents from the water-soluble extract.NMR,MS and other related spectroscopic analyses were used to identify their structures,and a Griess method was used to evaluate their inhibitory activity on lipopolysaccharide-induced inflammation of BV-2 cells.Results Twelve compounds were isolated and identified as tinnevellin-8-O-β-D-glucopyranoside(1),emodin-8-O-β-D-glucopyranoside(2),(2R,3S)-ceplignan(3),(-)-olivil-9’-O-β-D-glucopyranoside(4),(-)-massoniresinol-3a-O-β-D-glucopyranoside(5),aurantiamide acetate(6),pinoresinol(7),8-hydroxypinoresinol(8),pinoresinol-4-O-β-D-glucopyranoside(9),prinsepiol-4-O-β-Dglucopyranoside(10),(2S)-hesperidin(11) and didymin(12).Conclusion Compounds 1―4 and 6 are firstly isolated from the genus Valeriana.Compound 3―4、6、9、11―12 showed inhibition on the production of neuroinflammatory factor NO induced by LPS in BV-2 cells,without any detectable influence on the cell viabilities.
作者
吴肸乐
李冉
李世伟
张丽花
韩立峰
张祎
王涛
王少峡
吴红华
WU Xi-le;LI Ran;LI Shi-wei;ZHANG Li-hua;HAN Li-feng;ZHANG Yi;WANG Tao;WANG Shao-xia;WU Hong-hua(State Key Laboratory of Component-based Chinese Medicine,Institute of Traditional Chinese Medicine,Tianjin University ofTraditional Chinese Medicine,Tianjin 301617,China;School of Integrative Medicine,Tianjin University of Traditional Chinese Medicine,Tianjin 301617,China)
出处
《中草药》
CAS
CSCD
北大核心
2022年第23期7331-7338,共8页
Chinese Traditional and Herbal Drugs
基金
国家重点研发计划(2018YFC1707904)
国家“重大新药创制”科技重大专项(2018ZX09735-002)
天津市中央引导地方科技发展专项(21ZYJDJC00080)。
